New York, Feb 27, 2026, 09:24 EST — Premarket
- 10x Genomics was indicated down 3.3% in premarket trading.
- CEO Serge Saxonov and CFO Adam Taich disclosed stock sales in recent regulatory filings.
- Investors are watching a March 3 management appearance for fresh demand signals.
10x Genomics shares were down about 3.3% at $21.40 in premarket trading on Friday, after slipping in extended hours following a sharp jump in the prior session. The stock closed at $22.13 on Thursday, up 12.6%. 1
The move puts the spotlight back on insider activity at a time when the stock has been swinging on thin news and positioning.
It also lands days before the company is due to speak publicly again, giving traders another checkpoint for whether the rally holds or fades.
Chief Financial Officer Adam Taich sold 8,968 shares on Feb. 23 at an average price of $18.5764, a regulatory filing showed. The filing said the shares were sold to cover tax withholding obligations tied to restricted stock units that vested. 2
Chief Executive Officer Serge Saxonov reported selling 9,632 shares on the same date at the same average price, according to a separate filing. It carried the same explanation on tax withholding linked to vesting. 2
Such sales are common around vesting dates, but they can still pinch sentiment when a stock has just posted an outsized daily gain.
Earlier this month, 10x Genomics reported quarterly revenue of $166.0 million and said it ended 2025 with $523.4 million in cash, cash equivalents and marketable securities. It forecast 2026 revenue of $600 million to $625 million, and Saxonov said the company executed “with discipline through a challenging environment.”
But 10x remains exposed to lab spending cycles, and any fresh sign that customers are delaying big purchases can quickly show up in orders and guidance.
The next clear catalyst on the calendar is a management fireside chat at TD Cowen’s annual health care conference on March 3, where investors will listen for updates on demand and the pace of instrument placements. 3
